EGFR Exon 19 Deletions: What the Biomarker Means

What an Exon 19 Deletion Is

EGFR exon 19 deletions remove a short stretch of coding sequence from the receptor's tyrosine-kinase domain. Most are in-frame deletions, meaning the reading frame is preserved while the local amino-acid sequence changes. Laboratories may report the exact deleted bases or protein notation rather than the shorthand 'exon 19 deletion', so the full variant wording matters when results are reviewed.

The alteration changes the balance between inactive and active kinase conformations. In a subset of NSCLC, that can make tumour growth more dependent on EGFR signalling and can help explain why an EGFR-directed therapy is considered. It does not prove that every cell in a tumour carries the alteration, that the finding is inherited, or that a response will occur.

How the Result Is Tested and Interpreted

Exon 19 deletions can be detected with a targeted PCR assay or a broader next-generation sequencing (NGS) panel. Tissue is often preferred when it is adequate, while plasma circulating-tumour-DNA testing can be useful when a tissue sample is unavailable or insufficient. A negative plasma result does not always exclude an alteration because the amount of tumour DNA in blood varies.

A good report identifies the specimen type, assay, variant notation, quality metrics, and whether the result is somatic or germline in scope. Companion-diagnostic status is specific to a device and indication; it should be checked in the current FDA device listing rather than inferred from the presence of an EGFR result on any commercial panel.

Treatment Context Without Overpromising

The FDA announcement linked below describes approval of osimertinib with platinum-based chemotherapy for locally advanced or metastatic NSCLC with an EGFR exon 19 deletion or exon 21 L858R substitution detected by an FDA-approved test. That statement is limited to the population, regimen, test, and date covered by the label; it is not a universal recommendation for every stage of lung cancer or every exon 19 result.

Resistance can emerge through additional EGFR changes, bypass signalling, histologic transformation, or a mixture of tumour subclones. When disease progresses, the next useful step is usually a clinician-led review of the new clinical picture and a validated re-biopsy or liquid-biopsy strategy where appropriate. This page explains the biomarker and evidence boundary; it does not diagnose cancer or select treatment.

Key Takeaways

• ·EGFR exon 19 deletions are usually in-frame kinase-domain alterations; the exact variant notation should be retained.
• ·Testing can use tissue or plasma, but specimen quality and assay design affect what a negative result means.
• ·The FDA treatment statement linked here is specific to locally advanced or metastatic NSCLC, an approved test, and the labelled regimen.
• ·A biomarker result is evidence for a clinical discussion, not a diagnosis, inherited-risk result, or stand-alone treatment instruction.